{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:16:53Z","timestamp":1791227813137,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.ygyno.2015.06.012","type":"journal-article","created":{"date-parts":[[2015,6,16]],"date-time":"2015-06-16T06:55:22Z","timestamp":1434437722000},"page":"363-368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["HIPEC in ovarian cancer: Treatment of a new era or is it the end of the pipeline?"],"prefix":"10.1016","volume":"139","author":[{"given":"P.","family":"Cascales-Campos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Feliciangeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Parrilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2015.06.012_bb0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2015.06.012_bb0015","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ygyno.2010.05.025","article-title":"The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm","volume":"118","author":"Bristow","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0020","doi-asserted-by":"crossref","first-page":"94-102","DOI":"10.1111\/IGC.0b013e31819915cb","article-title":"Influence of department volume on survival for ovarian cancer: results from a prospective quality assurance program of the Austrian Association for Gynecologic","volume":"19","author":"Marth","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2015.06.012_bb0025","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ygyno.2008.09.036","article-title":"Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review","volume":"112","author":"du Bois","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0030","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0035","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0140-6736(09)61338-6","article-title":"Ovarian cancer","volume":"374","author":"Hennessy","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2015.06.012_bb0040","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1272\/jnms.67.5","article-title":"It's what the surgeon doesn't see that kills the patient","volume":"67","author":"Sugarbaker","year":"2000","journal-title":"J. Nippon Med. Sch."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/GCO.0b013e32831f8f32","article-title":"Cytoreductive surgery and perioperative intraperitoneal chemotherapy for the treatment of advanced primary and recurrent ovarian cancer","volume":"21","author":"Sugarbaker","year":"2009","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0050","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1634\/theoncologist.2008-0275","article-title":"The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer","volume":"14","author":"Helm","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2015.06.012_bb0055","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1245\/s10434-006-9182-x","article-title":"A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei","volume":"14","author":"Yan","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0060","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0065","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/annonc\/mdl428","article-title":"A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma","volume":"18","author":"Yan","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0070","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1093\/annonc\/mdm137","article-title":"Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer","volume":"18","author":"Bijelic","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2015.06.012_bb0075","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ygyno.2014.11.072","article-title":"Gonzalez-Martin A.A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer","volume":"136","author":"Chiva","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2015.06.012_bb0080","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0085","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0090","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0095","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ygyno.2013.04.001","article-title":"Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study","volume":"130","author":"Landrum","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0100","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/annonc\/mdm518","article-title":"Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review","volume":"19","author":"Swart","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","article-title":"Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study","volume":"100","author":"Walker","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0110","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ygyno.2011.07.016","article-title":"Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a Gynecologic Oncology Group study","volume":"123","author":"Dizon","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0115","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ygyno.2012.03.027","article-title":"Progression-free and overall survival of a modified outpatient regimen of primary intravenous\/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer","volume":"125","author":"Barlin","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0120","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1093\/annonc\/mdm137","article-title":"Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer","volume":"18","author":"Bijelic","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0125","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0960-7404(99)00007-9","article-title":"The treatment of malignancy by hyperthermia","volume":"7","author":"Christophi","year":"1998","journal-title":"Surg. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0130","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1067\/msy.2002.119308","article-title":"Clinical application of hyperthermia combined with anticancer drugs for the treatment of solid tumors","volume":"131","author":"Takahashi","year":"2002","journal-title":"Surgery"},{"key":"10.1016\/j.ygyno.2015.06.012_bb0135","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1586\/14737140.1.1.142","article-title":"Intraperitoneal chemotherapy in the management of malignant disease","volume":"1","author":"Markman","year":"2001","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0140","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ijc.29011","article-title":"HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer","volume":"136","author":"Zivanovic","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2015.06.012_bb0145","first-page":"3944","article-title":"Selective lethal effect of supranormal temperatures on human neoplastic cells","volume":"36","author":"Giovanella","year":"1976","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2005.12.006","article-title":"Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma","volume":"100","author":"Trimble","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0155","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1245\/s10434-007-9792-y","article-title":"Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study","volume":"15","author":"de Bree","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0160","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00432-009-0667-4","article-title":"Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results","volume":"135","author":"Chua","year":"2009","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0165","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.ejso.2013.08.013","article-title":"Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer","volume":"40","author":"Cascales Campos","year":"2014","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0170","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","article-title":"Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm","volume":"114","author":"Chi","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0175","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ygyno.2007.03.019","article-title":"Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery","volume":"106","author":"Bae","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0180","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/jso.21682","article-title":"Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer","volume":"102","author":"Roviello","year":"2010","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0185","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1471-0528.2011.03207.x","article-title":"Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study","volume":"119","author":"Deraco","year":"2012","journal-title":"BJOG"},{"key":"10.1016\/j.ygyno.2015.06.012_bb0190","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1245\/s10434-012-2510-4","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients","volume":"19","author":"Bakrin","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0195","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1245\/s10434-014-3599-4","article-title":"Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC\/IV ovarian cancer","volume":"21","author":"Cascales-Campos","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0200","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s12094-009-0438-3","article-title":"The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer","volume":"11","author":"Mu\u00f1oz-Casares","year":"2009","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0205","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1245\/s10434-014-4049-z","article-title":"The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction","volume":"22","author":"Cascales-Campos","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0210","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","article-title":"Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study","volume":"22","author":"Spiliotis","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0215","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/bjc.1997.297","article-title":"Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells","volume":"75","author":"Hettinga","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2015.06.012_bb0220","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ijc.2910320103","article-title":"Concentration and time-dependent inter-relationships for antitumour drug cytotoxicities against tumour cells in vitro","volume":"32","author":"Rupniak","year":"1983","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2015.06.012_bb0225","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1245\/s10434-006-9305-4","article-title":"Short term exposure of cancer cells to micromolar doses of paclitaxel, with or without hyperthermia, induces long term inhibition of cell proliferation and cell death in vitro","volume":"14","author":"Michalakis","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0230","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s12094-007-0118-0","article-title":"Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals","volume":"9","author":"Mu\u00f1oz-Casares","year":"2007","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0235","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ejogrb.2011.04.036","article-title":"Heterogeneity in patients and methods. A problem for hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in ovarian carcinoma","volume":"158","author":"Cascales","year":"2011","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0240","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ygyno.2012.09.020","article-title":"Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case\u2013control study on survival in patients with two year follow-up","volume":"127","author":"Fagotti","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0245","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jso.21448","article-title":"Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer","volume":"101","author":"Kim","year":"2010","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0250","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1245\/s10434-014-3693-7","article-title":"Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case control study","volume":"21","author":"Le Brun","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0255","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ygyno.2004.05.044","article-title":"Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer","volume":"94","author":"Ryu","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0260","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/jso.23688","article-title":"Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients \u2014 a case\u2013control study","volume":"110","author":"Safra","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0265","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00268-007-9146-8","article-title":"Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients","volume":"31","author":"Cotte","year":"2007","journal-title":"World J. Surg."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0270","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.ejso.2009.03.004","article-title":"Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer \u2014 12-year single center experience","volume":"35","author":"Pavlov","year":"2009","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0275","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.amjsurg.2011.02.004","article-title":"Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms","volume":"202","author":"Parson","year":"2011","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.ygyno.2015.06.012_bb0280","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00423-014-1207-5","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single centre experience","volume":"399","author":"K\u00f6nigsrainer","year":"2014","journal-title":"Langenbeck's Arch. Surg."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815300354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815300354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T14:39:40Z","timestamp":1717943980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825815300354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0090825815300354"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.06.012","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIPEC in ovarian cancer: Treatment of a new era or is it the end of the pipeline?","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}